1. Introduction {#sec1-cancers-12-00294}
===============

Extended liver resection for primary and secondary hepatic malignancies is dependent on an adequate future liver remnant (FLR) volume \[[@B1-cancers-12-00294],[@B2-cancers-12-00294]\]. Preoperative measures to increase the volume of the FLR are effective in preventing posthepatectomy liver failure in marginally resectable disease, underlying liver cirrhosis, or heavily pretreated patients \[[@B3-cancers-12-00294],[@B4-cancers-12-00294]\]. These interventions include selective occlusion of the contralateral portal venous supply via portal vein ligation or portal vein embolization (PVE) \[[@B5-cancers-12-00294]\]. Portal vein ligation requires a laparoscopy or laparotomy with manipulation of the hepatic hilum that can render a subsequent resection more challenging, whereas PVE can be performed percutaneously with comparable hypertrophy rates \[[@B5-cancers-12-00294]\]. Therefore, PVE has been used at most hepatobiliary units as the primary intervention to increase the FLR. However, tumor progression during the hypertrophy period after PVE has remained an unsolved issue and prevents subsequent hepatectomy in up to 40% of patients \[[@B6-cancers-12-00294],[@B7-cancers-12-00294]\]. An alternative approach to portal vein ligation and PVE is associating liver partition and portal vein ligation for staged hepatectomy (ALPPS). Unfortunately, the results for ALPPS in patients with primary liver malignancies have been disappointing due to high perioperative morbidity and mortality rates \[[@B8-cancers-12-00294]\].

Recently, there has been increasing interest in radioembolization with ^90^Y-microspheres (also known as selective internal radiation therapy), as this treatment offers local tumor control with simultaneous hypertrophy of the contralateral lobe \[[@B9-cancers-12-00294],[@B10-cancers-12-00294]\]. Radioembolization (RE) is a minimally invasive procedure with transarterial delivery of ^90^Y-loaded microspheres made of glass (diameter: 25 ± 10 µm; activity per particle: 2500 Bq) or resin (diameter: 35 ± 10 µm; activity per particle: 50 Bq) \[[@B11-cancers-12-00294],[@B12-cancers-12-00294]\]. The first reports of treatment with ^90^Y-microspheres dates back to 1965 for patients with unresectable pancreatic and liver cancer \[[@B13-cancers-12-00294]\]. The concept of radioembolization-induced liver hypertrophy, also termed as radiation lobectomy, was first described in 2008 in patients with colorectal liver metastasis, and in 2009 in patients with hepatocellular carcinoma (HCC) \[[@B14-cancers-12-00294],[@B15-cancers-12-00294]\].

Since then, several cohort studies have reported the effectiveness of RE-induced contralateral liver hypertrophy in predominantly primary liver cancer \[[@B16-cancers-12-00294],[@B17-cancers-12-00294]\]. Moreover, a recent secondary analysis of a randomized trial revealed a higher resectability rate for patients with initially unresectable colorectal liver metastasis (CRLM) who received RE and chemotherapy compared to chemotherapy only \[[@B18-cancers-12-00294]\]. Hence, RE seems to be a promising approach for multimodal treatment of primary and secondary liver malignancies. However, the effective hypertrophy rate and its simultaneous impact on local tumor control remains unclear. Although several reviews about ^90^Y-microspheres have been reported in the literature before, the effectiveness of ^90^Y-microspheres in liver preconditioning and its simultaneous oncological outcome for the treatment of primary and/or secondary liver malignancies have not been thoroughly assessed \[[@B10-cancers-12-00294],[@B12-cancers-12-00294],[@B16-cancers-12-00294],[@B17-cancers-12-00294],[@B19-cancers-12-00294],[@B20-cancers-12-00294]\].

Therefore, the aim of this analysis was to summarize the evidence of RE as a method to induce contralateral liver hypertrophy with simultaneous ipsilateral control of tumor growth.

2. Results {#sec2-cancers-12-00294}
==========

A total of 189 studies were identified by the search criteria. Following abstract and full-text screening for eligibility, 173 studies were excluded according to our inclusion criteria. Finally, 16 studies remained eligible for inclusion in this review ([Figure 1](#cancers-12-00294-f001){ref-type="fig"}).

2.1. Baseline Characteristics {#sec2dot1-cancers-12-00294}
-----------------------------

The 16 included studies comprised a total of 602 patients who underwent RE for primary and/or secondary liver malignancies \[[@B14-cancers-12-00294],[@B15-cancers-12-00294],[@B21-cancers-12-00294],[@B22-cancers-12-00294],[@B23-cancers-12-00294],[@B24-cancers-12-00294],[@B25-cancers-12-00294],[@B26-cancers-12-00294],[@B27-cancers-12-00294],[@B28-cancers-12-00294],[@B29-cancers-12-00294],[@B30-cancers-12-00294],[@B31-cancers-12-00294],[@B32-cancers-12-00294],[@B33-cancers-12-00294],[@B34-cancers-12-00294]\]. Patient characteristics and outcomes are summarized in [Table 1](#cancers-12-00294-t001){ref-type="table"}.

The median age was 68 (range: 59--79) with a predominance of men (76%). Pathological findings revealed 490 (81%) primary liver malignancies. Of these, 462 (94%) patients had hepatocellular carcinoma and 28 (6%) patients had cholangiocarcinoma. A total of 136 (22%) patients suffered from secondary liver malignancies, of which 86 (77%) patients had CRLM. Underlying liver cirrhosis was documented in 375 cases (62%). Only 8 studies (*n* = 42 patients) reported on the presence of portal hypertension (PHTN) and 9 studies (*n* = 73 patients) described the frequency of portal vein thrombosis (PVT). Prior to RE, a total of 136 patients received the following therapies: 102 patients (17%) had prior chemotherapy (CTx), 24 patients (4%) had prior local ablative therapy (LATx), and 10 patients (2%) had prior hepatectomy (Hx).

2.2. Contralateral Lobe Hypertrophy {#sec2dot2-cancers-12-00294}
-----------------------------------

The assessment of the RE-induced contralateral lobe hypertrophy is detailed in [Table 2](#cancers-12-00294-t002){ref-type="table"}. The most commonly used modality of RE was ^90^Y-glass-microspheres (*n* = 435, 72%), whereas ^90^Y-resin-microspheres were used in 167 (28%) patients. A total of 585 (97%) patients received unilobar treatment. Bilobar treatment was conducted in 17 patients. Three studies reported on segmental RE in 15 out of 169 patients (9%) \[[@B22-cancers-12-00294],[@B25-cancers-12-00294],[@B28-cancers-12-00294]\]. The median applied activity of yttrium was 2.1 GBq, with a median administered dose of 121 Gy.

Only patients with unilobar treatment were assessed for measurements of contralateral liver lobe hypertrophy. The mean follow-up (F/U) was 5 months and ranged between 4 weeks and 18 months. The median kinetic growth rate (KGR) per week was 0.7% and declined continuously over time, although the maximum degree of relative contralateral hypertrophy exceeding 40% was achieved after 9 months. The ratio between future liver remnant and total liver volume (FLR/TLV) at the baseline ranged between 23.4% and 49.6%, and the FLR/TLV after RE between 27.0% and 68.6%. The KGR between the applicated microspheres showed a similar distribution: 0.8% (range: 0.3%-3%) for glass-microspheres only (*n* = 408), and 0.8% (range: 0.4--1.3%) for resin-microspheres only (*n* = 163). Only one study used both glass and resin microspheres for a total of 34 patients \[[@B21-cancers-12-00294]\]. With regard to the underlying malignancy, the median KGR was 0.7% (range: 0.3--2.5%) in primary malignancies (*n* = 316), 0.8% (range: 0.7--1.3%) in secondary malignancies (*n* = 54), and 0.8% (range: 0.7--1.7%) in both primary and secondary malignancies (*n* = 201). Three studies assessed entirely cirrhotic patients in a cohort of HCC \[[@B21-cancers-12-00294],[@B28-cancers-12-00294],[@B32-cancers-12-00294]\]. These patients had a similar KGR of 0.7% per week (range: 0.6--1.1%) compared to patients without liver cirrhosis with a KGR per week of 0.7% (range: 0.3--1.3%). Further subgroup analysis of patients with PVT, PHTN, previous chemotherapy, previous local ablative therapy, or previous hepatic surgery were not feasible due to heterogeneous patient cohorts and data.

2.3. Oncological Outcome {#sec2dot3-cancers-12-00294}
------------------------

Details about the oncological outcome following RE were reported in 12 studies (*n* = 357 patients) and are displayed in [Table 3](#cancers-12-00294-t003){ref-type="table"}.

In the studies, 57 out of 360 patients (16%) developed tumor progression during a median F/U period of 11 months (range: 1--49 months). In the ipsilateral liver lobe, a total of 11 patients had progressive disease, whereas tumor progression was accounted in the contralateral liver lobe in a total of 42 patients, and 3 patients had progressive disease without further specification. Only three patients suffered from distant extrahepatic tumor progress.

Tumor response according to response evaluation criteria in solid tumors (RECIST) criteria following RE was stated in six studies (*n* = 118 patients). According to RECIST, complete and/or partial response was observed in 36 patients (31%), stable disease was noted in 65 patients (55%), and a total of 17 patients showed evidence of progressive disease (14%). Two studies (*n* = 44 patients) reported tumor response corresponding to the European Association for the Study of the Liver (EASL) and the World Health Organization (WHO) criteria \[[@B26-cancers-12-00294],[@B34-cancers-12-00294]\]. According to WHO criteria, partial response was demonstrated in 11 patients, stable disease in 30 patients, and progressive disease in 3 patients. According to EASL criteria, complete response was depicted in 9 patients, partial response in 14 patients, and stable disease in 21 patients. Ten studies provided data on liver surgery following RE in primarily unresectable liver tumors, resulting in 109 out of 362 patients (30%) who underwent secondary surgery. The time interval of surgery after the last treatment of RE was reported in three studies with time points ranging between 2 and 30 weeks after RE \[[@B25-cancers-12-00294],[@B26-cancers-12-00294],[@B34-cancers-12-00294]\].

2.4. Post-RE Treatment and Complications {#sec2dot4-cancers-12-00294}
----------------------------------------

Peri-interventional complications and adverse effects following RE are outlined in [Table 4](#cancers-12-00294-t004){ref-type="table"}.

Twelve studies disclosed RE-related adverse effects in a total of 326 patients with varying details as follows: fatigue (*n* = 78), abdominal pain (*n* = 41), hyperbilirubinemia (*n* = 22), vomiting---fever/chills without infection (*n* = 9), decreased appetite (*n* = 8), weight loss (*n* = 5), ascites (*n* = 3), encephalopathy (*n* = 1), leukopenia (*n* = 1), acute cholecystitis (*n* = 1), and pseudoaneurysm at the puncture site (*n* = 1). One study graded the adverse effects in line with the Radiation-Lobectomy Clinical Toxicity (RLCT) grade \[[@B26-cancers-12-00294]\]. Four studies reported on postoperative complications after RE following hepatectomy according to Clavien--Dindo classification, resulting in a postoperative morbidity rate (Clavien--Dindo grade III-IVb) of 15% (*n* = 16 patients). A total of three patients (3%) died postoperatively within 90 days after surgery (Clavien--Dindo grade V) \[[@B25-cancers-12-00294],[@B26-cancers-12-00294],[@B29-cancers-12-00294],[@B34-cancers-12-00294]\].

2.5. Quality Assessment {#sec2dot5-cancers-12-00294}
-----------------------

All studies were non-comparative cohort studies or clinical series, except for one matched-pair analysis \[[@B23-cancers-12-00294]\]. The methodological quality of the included studies is summarized according to the Methodological Index for Non-Randomized Studies (MINORS) criteria in [Table S1](#app1-cancers-12-00294){ref-type="app"}. The median MINORS score was 10 (range: 7--16). Only patients with RE were assessed for quality analysis by the MINORS scale. Thus, the control group (cohort of patients with PVE) in the study by Garlipp et al. was not considered for further MINORS score evaluation \[[@B23-cancers-12-00294]\]. All identified studies were in retrospective fashion, except for one study \[[@B27-cancers-12-00294]\]; however, this was non-randomized and not controlled.

3. Discussion {#sec3-cancers-12-00294}
=============

The present review demonstrates a significant amount of contralateral lobe hypertrophy following RE with a median KGR of 0.7% per week. Up to 84% of the treated patients showed a local tumor control following RE. Finally, 30% of individuals with primarily unresectable hepatic malignancies underwent subsequent hepatic resection with decent postoperative morbidity and mortality rates in heavily pretreated patients. However, the evidence on RE-induced liver hypertrophy is primarily based on retrospective cohort studies. The impact of selection bias in these retrospective studies remains unknown and resulted in a low MINORS score. The only available prospective study was published in a small cohort of 24 patients with palliative treatment of advanced hepatocellular carcinoma \[[@B31-cancers-12-00294]\]. Despite its prospective design, this study lacks information on the effect of RE on hypertrophy in subgroups at high risk of poor hypertrophy, such as patients with diabetes, advanced cirrhosis, and portal vein thrombosis (PVT). Although the impact of underlying liver cirrhosis on the induction of contralateral hypertrophy following RE remains controversial with comparable KGR compared to patients without liver cirrhosis, future studies need to document clinicopathologic characteristics to provide clinicians with more precise information on the regenerative potential of RE.

The optimal FLR volume for safe hepatectomy is still uncertain. An FLR and TLV ratio of 20--30% has been suggested as a threshold for patients with normal liver parenchyma and 40--45% for patients with liver cirrhosis \[[@B35-cancers-12-00294]\]. To date, the impact of RE-induced contralateral liver hypertrophy has been assessed in two systematic reviews, including seven and eight studies, respectively \[[@B10-cancers-12-00294],[@B17-cancers-12-00294]\]. Teo et al. reported only the relative degree of hypertrophy regardless of the oncological outcome, and no data on the ratio of FLR to TLV. Similarly, Braat et al. assessed only the degree of contralateral liver hypertrophy irrespective of FLR/TLV, but in combination with the oncological response according to RECIST criteria. In both reviews, the small number of patients and the varying time points of volume assessments resulted in a huge range of relative degrees of liver hypertrophy between 7% to 62% and 26% to 42%, respectively. However, in the daily routine, the ratio of FLR and TLV rather than the relative degree of liver lobe hypertrophy is used to determine a safe resectability. To overcome the disadvantage of varying time points of hypertrophy assessments due to the given data in the literature, we thoroughly analyzed the KGR per week for each study in relation to the earliest F/U imaging. The KGR is a more reliable parameter than the relative degree of liver hypertrophy and might predict posthepatectomy liver failure \[[@B36-cancers-12-00294]\]. Additionally, the KGR enables a rough prediction of the required time interval to the intended FLR/TLV threshold. In fact, kinetic studies revealed that RE induces steady hypertrophy rates over time, although there is a distinct decline of hypertrophy after 3 months \[[@B27-cancers-12-00294]\]. In contrast to RE, PVE passes in a plateau phase after 3 weeks. \[[@B37-cancers-12-00294]\]. Still, the best time point for a volumetric assessment following preconditioning modalities remains unclear. According to a recent randomized trial comparing the ALPPS procedure to PVE, PVE induced a mean KGR of 6 ± 5% \[[@B38-cancers-12-00294]\]. Although the present review depicted a substantial lower KGR for RE with values ranging between 0.3% and 2.5%, certain patient selection without heavily pretreated patients might overcome these low values, and this needs to be addressed in prospective trials. In case of insufficient hypertrophy levels after RE, the option of PVE/portal vein ligation or even a combination of transarterial and transportal RE is feasible \[[@B25-cancers-12-00294],[@B39-cancers-12-00294],[@B40-cancers-12-00294]\]. To date, the only comparative study between RE and PVE, a matched-pair analysis, demonstrated a significantly higher mean relative hypertrophy level of 62% following PVE compared to a mean relative hypertrophy level of 29% following RE \[[@B23-cancers-12-00294]\]. However, the study design shows a strong selection and reporting bias by including two cohorts from different institutions with heavily pretreated patients in the RE group \[[@B38-cancers-12-00294]\].

Despite the need for larger injection volumes and subsequent higher microembolic effects for resin-based spheres due to lower relative activity, no difference has been noted thus far in clinical response \[[@B41-cancers-12-00294]\]. Of note, RE by microspheres does not result in macrovascular embolization; thus, the hypertrophy of the liver is probably induced by radiation effects \[[@B14-cancers-12-00294],[@B21-cancers-12-00294],[@B42-cancers-12-00294]\]. Ultimately, the impact of dose-dependent and activity-related hypertrophy effects of ^90^Y-microspheres, as well as the role of segmental RE, remains unclear due to the lack of provided data.

RE is a well-tolerated and safe intervention to treat patients with liver malignancies \[[@B43-cancers-12-00294]\]. Certain clinical conditions such as PVT and/or PHTN with impaired liver function limit the application of transarterial chemoembolization but not the use of RE \[[@B44-cancers-12-00294]\]. In comparison to transarterial chemoembolization, a postembolization syndrome or RE-induced liver disease is a rare event \[[@B12-cancers-12-00294],[@B45-cancers-12-00294]\]. As revealed by our results, not all included studies reported on adverse events. In literature, the incidence of RE-induced liver disease (REILD) is up to 10% \[[@B46-cancers-12-00294]\]. However, there is currently no unifying definition of REILD and the reporting of adverse effects is highly variable \[[@B47-cancers-12-00294]\]. In our analysis, RE-related hepatotoxicity was below 10%.

According to the RECIST criteria, radiologic tumor response (partial and complete response) following RE displayed promising effects with response rates up to 96% in liver malignancies \[[@B23-cancers-12-00294]\]. Recently, a randomized-controlled trial reported delayed disease progression in the liver following the addition of RE to standard chemotherapy in unresectable CRLM \[[@B48-cancers-12-00294]\]. This might potentially increase resectability if subsequent liver surgery was planned \[[@B18-cancers-12-00294]\]. To date, only a few retrospective clinical series with subsequent hepatic resections following RE are available in the literature, but with favorable oncological and surgical results. \[[@B25-cancers-12-00294],[@B49-cancers-12-00294],[@B50-cancers-12-00294]\]. A time interval of 2 to 3 months between the last RE application and hepatic resection is recommended as optimal timing for resection \[[@B51-cancers-12-00294]\]. However, there is also evidence for feasible secondary liver resection even 20 months following RE (*n* = 12) with acceptable morbidity (50%) and 90-day mortality (8%) rates \[[@B52-cancers-12-00294]\]. Unfortunately, long-term results following RE and secondary liver resection are limited in the literature, but survival rates of up to 86% at 3 years and recurrence-free survival of 34 months in HCC seems to be promising for future trials \[[@B34-cancers-12-00294]\]. Nevertheless, the only prospective pilot study of RE application with subsequent surgery revealed progressive liver and extrahepatic disease following RE in 3 out of 30 patients with subsequent contraindication for surgery \[[@B53-cancers-12-00294]\].

The present review revealed several limitations for the findings of the included studies. There was a high heterogeneity with regard to RE modality, follow-up period, underlying pathology, and prior treatment before RE application across the studies. The measurements of contralateral liver lobe hypertrophy were performed at different time points, resulting in a certain effect imprecision, although the KGR was calculated to provide more robust data. Further, RE-induced adverse events were stated in 75% of the included studies, but with highly variable reporting. This might have resulted in an underestimation of adverse events following RE.

4. Materials and Methods {#sec4-cancers-12-00294}
========================

A systematic literature research was conducted according to the PRISMA guidelines and a defined study protocol \[[@B54-cancers-12-00294]\].

4.1. Search Strategy {#sec4dot1-cancers-12-00294}
--------------------

The MEDLINE (via PubMed), EMBASE, and Cochrane Library databases were searched for studies published between 1 January 2008 and 3 January 2020. The search was limited to studies published after 2008, as the concept of radioembolization-induced liver hypertrophy was first described in 2008 \[[@B14-cancers-12-00294]\]. A combination of the following terms as free text words and/or medical subject headings was used as search strategy: "TARE"\[All Fields\] OR "Yttrium 90"\[All Fields\] OR "selective internal radiation therapy"\[All Fields\] OR "radioembolisation"\[All Fields\] OR "radioembolization"\[All Fields\] AND ("hypertrophy"\[MeSH Terms\] OR "hypertrophy"\[All Fields\] OR "volumetric"\[All Fields\] OR "liver remnant"\[All Fields\] OR "liver resection"\[All Fields\] OR "lobectomy"\[All Fields\] OR "hepatectomy"\[All Fields\]) AND ("2008/01/01"\[PDAT\]: "2020/01/03"\[PDAT\]).

Titles and abstracts of retrieved studies were screened by two reviewers (E.B., E.R.), and full texts were obtained for potentially relevant studies. Reference lists of relevant studies were crosschecked for additional studies.

4.2. Eligibility Criteria {#sec4dot2-cancers-12-00294}
-------------------------

All studies that reported on quantitative contralateral liver hypertrophy following radioembolization in patients with primary or secondary liver malignancies were included. We excluded studies without data on volumetric changes of the contralateral liver lobe, reports with less than five patients, and review articles.

4.3. Data Collection and Definitions {#sec4dot3-cancers-12-00294}
------------------------------------

Data extraction was carried out by two reviewers (E.B., E.R.). The following data were extracted: author, publication date, study design, total number of patients, age, sex, modality of radioembolization, radioembolization applicated liver site, dose, activity, time points of follow-up imaging, modality of follow-up imaging, hypertrophic volumetric change, tumor response following radioembolization, radioembolization-related adverse effects, pathology, underlying liver disease, prior treatment to radioembolization, and treatment following radioembolization and postoperative complications.

The FLR was defined as the volume of the contralateral liver lobe divided by the TLR. The degree of relative hypertrophy was defined as the increase of future liver remnant volume following RE compared to the volume of the FLR at the baseline. The primary outcome was the KGR per week assessed by the means of the relative increase FLR volume. If the KGR was not provided in the studies, the following formula was used to calculate the KGR: $${KGR} = \ \frac{\left( \frac{FLR}{TLV} \right){{after}\ {treatment}} - \ \left( \frac{FLR}{TLV} \right){baseline}}{{{time}\ }\left( {{weeks}\ {elapsed}\ {between}\ {baseline}\ {and}\ {treatment}} \right)}$$

The following data were recorded for each study: kind of malignancy; underlying liver disease; presence of PHTN or PVT; tumor response (according to RECIST, EASL, and/or WHO criteria) \[[@B55-cancers-12-00294],[@B56-cancers-12-00294]\]; post-radioembolization complications; and pre- and post-radioembolization treatments such as chemotherapy, radiation therapy, local ablative therapy (LATx), portal vein embolization (PVE), surgery, and postoperative morbidity. In addition, details of the performed surgical procedure were documented.

### Risk-of-Bias Assessment

The Methodological Index for Non-Randomized Studies (MINORS) was applied to assess the quality of selected studies by two independent reviewers (E.B., E.R.) \[[@B57-cancers-12-00294]\].

4.4. Statistical Analysis {#sec4dot4-cancers-12-00294}
-------------------------

The KGR and the relative rate of hypertrophy was presented as reported in the original articles or calculated as described above. A pooling of data was performed, and variables were presented as median and range. SPSS software version 24 was used for data tabulation.

5. Conclusions {#sec5-cancers-12-00294}
==============

In summary, the available literature shows a considerable degree of RE-induced contralateral lobe hypertrophy with favorable tumor control and even secondary surgery following RE for hepatic malignancies. However, the definitive role of RE in the treatment algorithm of liver tumors remains unclear due to missing randomized controlled trials comparing RE with standard therapies. Therefore, the promising potential of RE as an additional strategy in the multimodal treatment of liver malignancies needs to be investigated in prospective studies, particularly, with reference to the effective KGR, oncological outcome, and RE-related adverse effects.

The following are available online at <https://www.mdpi.com/2072-6694/12/2/294/s1>: Table S1: Quality assessment of studies according to MINORS score.
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cancers-12-00294-t001_Table 1

###### 

Baseline characteristics of patients in included papers.

  -----------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                      Year   Pts   Age ^†^    Sex (M/F)   Pathology   Underlying Liver Disease   Prior Therapy   MINORS Score
  ------------------------------------------- ------ ----- ---------- ----------- ----------- -------------------------- --------------- --------------
  Edeline \[[@B21-cancers-12-00294]\]         2013   34    n/a        29:5        HCC: 34     Cirrhosis: 34\             None            10
                                                                                              PHTN: 19\                                  
                                                                                              PVT: 14                                    

  Fernandez-Ros \[[@B22-cancers-12-00294]\]   2014   83    66         61:22       HCC: 52\    Cirrhosis: 44\             CTx: 29         7
                                                                                  CCC: 4\     PHTN: none\                                
                                                                                  CRLM: 13\   PVT: 8                                     
                                                                                  NCRLM: 14                                              

  Gaba \[[@B15-cancers-12-00294]\]            2009   20    67 *^§^*   16:4        HCC: 17\    Cirrhosis: 17\             CTx: 16\        9
                                                                                  CCC: 3      PHTN: -\                   LATx: 3\        
                                                                                              PVT: 5                     Hx: 3           

  Gabr \[[@B34-cancers-12-00294]\]            2018   31    63         n/a         HCC: 31     Cirrhosis: 14              LATx: 1\        16
                                                                                                                         Hx: 2           

  Garlipp \[[@B23-cancers-12-00294]\]         2014   26    59.2 ^§^   12:14       CRLM: 12\   Cirrhosis: none\           CTx: 26         10 (16)
                                                                                  NCRLM: 14   PHTN/PVT: -                                

  Goebel \[[@B24-cancers-12-00294]\]          2017   75    67         60:15       HCC: 75     Cirrhosis: 55\             None            9
                                                                                              PHTN: -\                                   
                                                                                              PVT: 8                                     

  Jakobs \[[@B14-cancers-12-00294]\]          2008   32    n/a        15:17       CRLM: 20\   Cirrhosis: none\           CTx/RTx: -      10
                                                                                  Other: 12   PHTN/PVT: -                                

  Justinger \[[@B25-cancers-12-00294]\]       2015   13    79         8:5         CRLM: 13    Cirrhosis: none\           CTx: 3\         9
                                                                                              PHTN/PVT: -                PVE: 1          

  Lewandowski \[[@B26-cancers-12-00294]\]     2016   13    62         9:4         HCC: 10\    Cirrhosis: 5\              CTx: 1\         11
                                                                                  CCC: 2\     PHTN: none\                Hx: 1           
                                                                                  CRLM: 1     PVT: -                                     

  Orcutt \[[@B27-cancers-12-00294]\]          2018   25    71         21:4        HCC: 17\    Cirrhosis: 13\             none            11
                                                                                  CCC: 3\     PHTN: 6\                                   
                                                                                  CRLM: 5     PVT: none                                  

  Palard \[[@B28-cancers-12-00294]\]          2017   73    67.9 ^§^   66:7        HCC         Cirrhosis: 73\             CTx: 5\         10
                                                                                              PHTN/PVT: -                LATx: 18\       
                                                                                                                         Hx: 4           

  Rayar \[[@B29-cancers-12-00294]\]           2015   8     68         3:5         CCC: 8      Cirrhosis: none\           CTx: 8\         10
                                                                                              PHTN/PVT: -                PVE: 1          

  Teo \[[@B30-cancers-12-00294]\]             2014   17    72         12:5        HCC         Cirrhosis: 12\             none            10
                                                                                              PHTN: 11\                                  
                                                                                              PVT: -                                     

  Teo \[[@B31-cancers-12-00294]\]             2018   24    66         24:0        HCC         Cirrhosis: 16\             none            10
                                                                                              PHTN: 6\                                   
                                                                                              PVT: 6                                     

  Theysohn \[[@B32-cancers-12-00294]\]        2014   45    72 ^§^     36:9        HCC         Cirrhosis: 45\             \-              10
                                                                                              PHTN/PVT: -                                

  Vouche \[[@B33-cancers-12-00294]\]          2013   83    68         66:17       HCC: 67\    Cirrhosis: 47\             CTx: 14         7
                                                                                  CCC: 8\     PHTN: -\                                   
                                                                                  CRLM: 8     PVT: 32                                    
  -----------------------------------------------------------------------------------------------------------------------------------------------------

Pts: patients, M/F: male-to-female ratio, MINORS: Methodological Index for Non-Randomized Studies, HCC: hepatocellular carcinoma, CCC: cholangiocarcinoma, CRLM: colorectal liver metastasis, NCRLM: non-colorectal liver metastasis, PHTN: portal hypertension, PVT: portal vein thrombosis, CTx: chemotherapy, PVE: portal vein embolization, RTx: radiation therapy, LATx: local ablative therapy, Hx: hepatectomy, -: data not available. ^†^ values are median; ^§^ values are mean.

cancers-12-00294-t002_Table 2

###### 

Overview of radioembolization (RE)-induced hypertrophy.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                      RE Mod   RE Dose/Activity ^†^   Mean F/U\                     KGR/Week in %   FLR/TLV at Baseline in %   FLR/TLV After ^90^Y in %   Mean Degree of Relative Hypertrophy Level in %
                                                                              Period Following RE                                                                                 
  ------------------------------------------- -------- ---------------------- ----------------------------- --------------- -------------------------- -------------------------- ------------------------------------------------
  Edeline \[[@B21-cancers-12-00294]\]         G+R      122 Gy, 2.5 GBq        3 mo                          1.1             42.3                       55.5                       \+ 29

  Fernandez-Ros \[[@B22-cancers-12-00294]\]   R        \-                     4--8 wks\                     0.8\            29.0 ^§^\                  32 ^§^\                    \+ 12.6\
                                                                              10--26 wks\                   -\              -\                         40 ^§^\                    + 23.0\
                                                                              \>26 wks                      -               -                          50 ^§^                     + 39.3

  Gaba \[[@B15-cancers-12-00294]\]            G        132 Gy\                18 mo                         1.9             42.9                       68.6                       \+ 40.0
                                                       2.2 GBq                                                                                                                    

  Gabr \[[@B34-cancers-12-00294]\]            G        140 Gy                 2.9 mo                        2.5 \*          35.0 \*                    45.0 \*                    \+ 23.3 (unilobar)\
                                                                                                                                                                                  + 9 (segmental)

  Garlipp \[[@B23-cancers-12-00294]\]         R        1.2 GBq                46 days ^†^                   0.7             23.4 ^§^                   27.9 ^§^                   \+ 29; + 25.3 †

  Goebel \[[@B24-cancers-12-00294]\]          G        113 Gy ^§^\            1 mo\                         0.9\            33.9\                      37.6\                      \+ 16.9\
                                                       2.9 GBq ^§^            3 mo\                         0.8\            -\                         44.2\                      + 29.3\
                                                                              6 mo\                         0.7\            -\                         50.9\                      + 40.9\
                                                                              9 mo (*n* = 61)               0.5             -                          53.1                       + 43.4

  Jakobs \[[@B14-cancers-12-00294]\]          G        120 Gy                 4 wks                         0.6 \*          31.2 \*                    44.4 \*                    \+ 21.2; + 8.7 †

  Justinger \[[@B25-cancers-12-00294]\]       R        1.3 GBq                8 wks                         1.3             30.4 ^§^                   40.4 ^§^                   \-

  Lewandowski \[[@B26-cancers-12-00294]\]     G        154 Gy                 40 days ^†^                   1.7             33.0                       43.9                       \+ 30

  Orcutt \[[@B27-cancers-12-00294]\]          G        132 Gy                 1 mo; 1.1 mo ^†^\             0.8\            33.0\                      37.5\                      \+ 16.7; + 11 ^†^\
                                                                              3 mo; 3.8 mo ^†^\             0.5\            -\                         41.9\                      + 31.1; + 17.4 ^†^\
                                                                              6 mo; 6.3 mo ^†^              0.4             -                          44.5                       + 38.5; + 31.3 ^†^

  Palard \[[@B28-cancers-12-00294]\]          G        \-                     5.9                           0.7             49.6 ^§^                   66.9 ^§^                   \+ 35.4

  Rayar \[[@B29-cancers-12-00294]\]           G        2 GBq                  7.6 mo ^†^                    0.3             27.2                       35.9                       \+ 8.7

  Teo \[[@B30-cancers-12-00294]\]             R        \-                     5.7 mo ^†^                    0.5             32.7 ^§^                   45.5 ^§^                   \+ 34.2

  Teo \[[@B31-cancers-12-00294]\]             R                               4--6 wks\                     0.3\            31.7 ^§^\                  33.8 ^§^\                  \+ 5.6; + 3 ^†^\
                                                                              8--12 wks (*n* = 22)          -               -                          39.7 ^§^                   + 21.2; + 9 ^†^

  Theysohn \[[@B32-cancers-12-00294]\]        G        \-                     1 mo\                         0.7\            35.0 ^§^\                  37.7\                      \+ 7.1\
                                                                              3 mo\                         0.8\            -\                         45.4\                      + 22.9\
                                                                              6 mo\                         0.6\            -\                         50.4 ^§^\                  + 30.8\
                                                                              9 mo\                         0.5\            -\                         54.0\                      + 35.7\
                                                                              12 mo                         0.4             -                          56.5                       + 40.1

  Vouche \[[@B33-cancers-12-00294]\]          G        112 Gy                 1 mo (*n* = 80)\              0.6\            24.4\                      27.0\                      \+ 7 †\
                                                                              45 days to 3 mo (*n* = 34)\   -\              -\                         27.8\                      + 24 †\
                                                                              3-6 mo (*n* = 42)\            -\              -\                         34.7\                      + 35 †\
                                                                              6-9 mo (*n* = 28)\            -\              -\                         34.3\                      + 36 †\
                                                                              \>9 mo (*n* = 25)             -               -                          36.4                       + 45 †
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

RE: radioembolization, mod: modality, F/U: follow-up, KGR: kinetic growth rate, FLR: future liver remnant, TLV: total liver volume, ^90^Y: treatment with yttrium, G: glass microspheres, R: resin microspheres, mo: months, wks: weeks, -: data not available. ^†^ values are median, ^§^ values are mean, \* only patients with unilobar treatment were considered.

cancers-12-00294-t003_Table 3

###### 

Overview of the oncological outcome.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                      Median F/U Period   Tumor Location\    Tumor Progress and Location    Tumor Response (RECIST)   Post-RE Surgery
                                                                  (Liver Site)                                                                
  ------------------------------------------- ------------------- ------------------ ------------------------------ ------------------------- -----------------
  Edeline \[[@B21-cancers-12-00294]\]         2 mo                Right: 23\         Ipsilateral: 3                 PR: 7\                    \-
                                                                  Left: 11                                          SD: 17\                   
                                                                                                                    PD: 3                     

  Fernandez-Ros \[[@B22-cancers-12-00294]\]   \-                  Right: 66\         \-                             \-                        Hx+LTx: 15
                                                                  Left: 17                                                                    

  Gaba \[[@B15-cancers-12-00294]\]            49 mo               Right: 20          None                           PR: 14\                   Hx: 1\
                                                                                                                    SD: 6                     LTx: 1

  Gabr \[[@B34-cancers-12-00294]\]            1 mo                Right: 25\         Location not specified: 3      CR: 9 ^\#^; 0 \*\         Hx: 31
                                                                  Left: 6                                           PR: 9 ^\#^; 8 \*\         
                                                                                                                    SD: 13 ^\#^; 20 \*\       
                                                                                                                    PD: 0 ^\#^; 3 \*          

  Garlipp \[[@B23-cancers-12-00294]\]         3 mo                Right: 26          Contralateral: 1               CR: 1\                    \-
                                                                                                                    PR: 5\                    
                                                                                                                    SD: 19\                   
                                                                                                                    PD: 1                     

  Goebel \[[@B24-cancers-12-00294]\]          \-                  Right: 75          \-                             \-                        \-

  Jakobs \[[@B14-cancers-12-00294]\]          \-                  Bilobar: 32        \-                             \-                        \-

  Justinger \[[@B25-cancers-12-00294]\]       5.1 mo              Right: 10\         Contralateral: 1\              \-                        Hx: 11
                                                                  Left: 1\           Extrahepatic: 1                                          
                                                                  Bilobar: 2                                                                  

  Lewandowski \[[@B26-cancers-12-00294]\]     6.3 mo              Right: 13          None                           CR: 1 ^\#^; 0 \*\         Hx: 13
                                                                                                                    PR: 5 ^\#^; 3 \*\         
                                                                                                                    SD: 8 ^\#^; 10 \*         

  Orcutt \[[@B27-cancers-12-00294]\]          6 mo                Right: 25          None                           \-                        \-

  Palard \[[@B28-cancers-12-00294]\]          12.5 mo             \-                 Ipsilateral: 8\                \-                        Hx: 9
                                                                                     Contralateral: 14                                        

  Rayar \[[@B29-cancers-12-00294]\]           16 mo               Right: 3\          None                           \-                        Hx: 8
                                                                  Bilobar: 5                                                                  

  Teo \[[@B30-cancers-12-00294]\]             6 mo                Right: 17          Contralateral: 4               CR: 2\                    Hx: 1
                                                                                                                    PR: 5\                    
                                                                                                                    SD: 6\                    
                                                                                                                    PD: 4                     

  Teo \[[@B31-cancers-12-00294]\]             12 mo               Right: 22Left: 2   Contralateral: 5               PR: 2\                    Hx: 8
                                                                                                                    SD: 17\                   
                                                                                                                    PD: 5                     

  Theysohn \[[@B32-cancers-12-00294]\]        \-                  Right: 45          \-                             \-                        \-

  Vouche \[[@B33-cancers-12-00294]\]          9 mo                Right: 83          Contralateral: 17              Missing: 79\              Hx: 5\
                                                                                                                    PD: 4                     LTx: 6

  Total                                       11 mo               Right: 453\        Ipsilateral: 11/360 (3%)\      CR: 3/118 (3%)\           109/362 (30%)
                                                                  Left: 37\          Contralateral: 42/360 (12%)\   PR: 33/118 (28%)\         
                                                                  Bilobar: 39        Extrahepatic: 1/360 (1%)\      SD: 65/118 (55%)\         
                                                                                     Not specified: 3/360 (1%)      PD: 17/118 (14%)          
  -------------------------------------------------------------------------------------------------------------------------------------------------------------

F/U: follow-up, RE: radioembolization, RECIST: response evaluation criteria in solid tumors, mo: months, Hx: hepatectomy, LTx: liver transplantation, CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease, -: data not available, \* according to World Health Organization (WHO) criteria, ^\#^ according to European Association for the Study of the Liver (EASL) response criteria.
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###### 

Overview of complications and adverse effects following radioembolization.

  ------------------------------------------------------------------------------------------------------------------------
  Author                                      RE-Related Hepatotoxicity   Other RE-Related AE       RE-Related Mortality
  ------------------------------------------- --------------------------- ------------------------- ----------------------
  Edeline \[[@B21-cancers-12-00294]\]         Hyperbilirubinemia: 6\      none                      2
                                              Ascites: 3\                                           
                                              Encephalopathy: 1                                     

  Fernandez-Ros \[[@B22-cancers-12-00294]\]   \-                          \-                        \-

  Gaba \[[@B15-cancers-12-00294]\]            Hyperbilirubinemia: 9       none                      none

  Gabr \[[@B34-cancers-12-00294]\]            Hyperbilirubinemia: 6       none                      none

  Garlipp \[[@B23-cancers-12-00294]\]         none                        Acute cholecystitis: 1\   none
                                                                          Leukopenia: 1             

  Goebel \[[@B24-cancers-12-00294]\]          \-                          \-                        \-

  Jakobs \[[@B14-cancers-12-00294]\]          none                        none                      none

  Justinger \[[@B25-cancers-12-00294]\]       none                        none                      none

  Lewandowski \[[@B26-cancers-12-00294]\]     none                        Fatigue: 10\              none
                                                                          Abdominal pain: 7\        
                                                                          Vomiting: 4               

  Orcutt \[[@B27-cancers-12-00294]\]          none                        Fatigue: 17\              none
                                                                          Abdominal pain: 15\       
                                                                          Vomiting: 8\              
                                                                          Appetite loss: 8\         
                                                                          Diarrhea: 2               

  Palard \[[@B28-cancers-12-00294]\]          \-                          \-                        \-

  Rayar \[[@B29-cancers-12-00294]\]           none                        none                      none

  Teo \[[@B30-cancers-12-00294]\]             none                        none                      none

  Teo \[[@B31-cancers-12-00294]\]             none                        none                      2

  Theysohn \[[@B32-cancers-12-00294]\]        \-                          \-                        \-

  Vouche \[[@B33-cancers-12-00294]\]          Hyperbilirubinemia: 1       Fatigue: 51\              none
                                                                          Abdominal pain: 19\       
                                                                          Fever: 9\                 
                                                                          Vomiting: 6\              
                                                                          Weight loss: 5\           
                                                                          Diarrhea:1\               
                                                                          Pseudoaneurysm: 1         

  Total                                       26/326 (8%)\                165/326 (50%)\            4/326 (1%)
                                              Hyperbilirubinemia: 22\     Fatigue: 78\              
                                              Ascites: 3\                 Abdominal pain: 41\       
                                              Encephalopathy: 1           Vomiting: 18\             
                                                                          Fever: 9\                 
                                                                          Appetite loss: 8\         
                                                                          Weight loss: 5\           
                                                                          Other: 6                  
  ------------------------------------------------------------------------------------------------------------------------

RE: radioembolization, AE: adverse effects, -: data not available.

[^1]: The authors E.B. and E.R. contributed equally to the work.
